LAUSANNE, Switzerland, June 14 /PRNewswire/ -- The Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, and sigma-tau Industrie Farmaceutiche Riunite SpA (sigma-tau), a leading Italian pharmaceutical group, announced the signature of a research and development (R&D) and commercialisation license agreement for istaroxime, a first-in-class luso-inotropic agent in clinical phase II for the treatment of acute heart failure syndromes.
